News
MGTA
--
0.00%
--
Mizuho Securities Sticks to Its Buy Rating for Magenta Therapeutics (MGTA)
Mizuho Securities analyst Difei Yang maintained a Buy rating on Magenta Therapeutics (MGTA) today and set a price target of $16.00. The company's shares
SmarterAnalyst · 01/11 20:26
Magenta Therapeutics announces expected 2021 highlights milestones
Magenta Therapeutics (MGTA) has announced four pipeline-expanding partnerships, presented clinical and pre-clinical data across our pipeline and secured the capital that we expect can fund our operations into 2023.MGTA-145: Three
Seekingalpha · 01/11 19:17
Magenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical Trials
Business Wire · 01/11 13:00
Magenta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is scheduled to present at the 39th Annual J.P. Morgan Hea...
Business Wire · 01/05 13:00
Magenta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is scheduled to present at the 39th Annual J.P. Morgan Hea...
BusinessWire · 01/05 10:00
Is MGTA A Good Stock To Buy Now?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 817 13F filings that hedge funds and well-known value investors ...
Insider Monkey · 12/17/2020 18:43
Magenta Therapeutics Announces Commencement Of First Phase 2 Clinical Trial Of MGTA-145 For Stem Cell Mobilization, Oral Presentation Of MGTA-145 Phase 1 Results, Update On Targeterd ADC Conditioning Program MGTA-117 At ASH Annual Meeting
Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145 Phase 1 Results and Update on Targeted ADC Conditioning Program MGTA-117
Benzinga · 12/07/2020 13:11
Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145 Phase 1 Results and Update on Targeted ADC Conditioning Program MGTA-117 at ASH Annual Meeting
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced final clinical results from its earlier completed Phase 1 clinical ...
Business Wire · 12/07/2020 13:00
Zacks.com featured highlights include: Blue Apron Holdings, Magenta Therapeutics, Credit Acceptance Corp, Clean Harbors and LogicBio Therapeutics
Zacks.com featured highlights include: Blue Apron Holdings, Magenta Therapeutics, Credit Acceptance Corp, Clean Harbors and LogicBio Therapeutics
Zacks · 12/04/2020 16:13
Zacks.com featured highlights include: Blue Apron Holdings, Magenta Therapeutics, Credit Acceptance Corp, Clean Harbors and LogicBio Therapeutics
Zacks.com featured highlights include: Blue Apron Holdings, Magenta Therapeutics, Credit Acceptance Corp, Clean Harbors and LogicBio Therapeutics
Zacks · 12/04/2020 16:13
Magenta Therapeutics, bluebird bio team up for MGTA-145 combo trial in sickle cell disease
Magenta Therapeutics (MGTA) and bluebird bio (BLUE) have entered into clinical trial collaboration to evaluate MGTA-145, a CXCR2 agonist, in combination with plerixafor, a CXCR4 antagonist, for mobilization and collection of stem cells
Seekingalpha · 12/04/2020 13:33
Magenta Therapeutics And bluebird bio Announce A Phase 2 Clinical Trial Collaboration To Evaluate Magenta's MGTA-145 For Mobilizing And Collecting Stem Cells In Adults And Adolescents With Sickle Cell Disease
Magenta Therapeutics (NASDAQ:MGTA) and bluebird bio, Inc. (NASDAQ:BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization
Benzinga · 12/04/2020 13:05
Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magentas MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease
Business Wire · 12/04/2020 13:00
Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta's MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease
Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease (SCD). The data from this clinical trial could provide proof-of-concept for MGTA-145, in combination with plerixafor, as the preferred mobilization regimen for patients with SCD. bluebird bio's experience with plerixafor as a mobilization agent in sickle cell disease aligns with Magenta's combination therapy approach, utilizing MGTA-145 plus plerixafor with potential to achieve safe, rapid and reliable mobilization of sufficient quantities of high-quality stem cells to improve outcomes associated with stem cell transplantation. Under the collaboration, the stem cells will be fully characterized, and Magenta will undertake preclinical studies to evaluate the ability of these cells to be gene corrected and engrafted in mouse models. The companies will co-fund the clinical trial and Magenta will retain all rights to its product candidate.
BusinessWire · 12/04/2020 10:00
Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta's MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease
Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults...
BusinessWire · 12/04/2020 10:00
Bet on 5 Top Stocks With Rising P/E for Spectacular Returns
Forget undervalued stocks, play these top-ranked stocks with rising P/E.
Zacks · 12/03/2020 13:52
Bet on 5 Top Stocks With Rising P/E for Spectacular Returns
Forget undervalued stocks, play these top-ranked stocks with rising P/E.
Zacks · 12/03/2020 13:52
The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12)
Benzinga · 11/13/2020 12:40
Magenta Therapeutics Appoints Steve Mahoney as Chief Financial and Operating Officer
Business Wire · 11/09/2020 13:00
Magenta Therapeutics Reports Recent Business Highlights and Third Quarter Financial Results
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today reported recent business highlights and financial results for the third quarter ended...
Business Wire · 11/05/2020 13:00
Webull provides a variety of real-time MGTA stock news. You can receive the latest news about Magenta Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About MGTA
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics to transform hematopoietic stem cell transplants for patients with immune and blood-based diseases. It maintains a platform with integrated and modular approach, which aims to reboot the blood and immune systems. The Company’s products include MGTA-145, MGTA-456, E478, and G100. The Company also developing a pipeline of small molecules; biologics, including antibody drug conjugates; and a cell therapy, which transplant options for many more patients with autoimmune diseases, blood cancers and genetic diseases. The Company’s C100 program targets HSCs, immune cells, and disease-causing cells, the C200 program targets HSCs and disease-causing cells and the C300 program targets only immune cells. This is achieved by tuning the antibodies to specific cellular markers or receptors that are expressed on the particular cell types.
More